# 2025年11月12日 - 专业文献速递

本期速递为您整理了最新的科研文献及AI评价，每一篇文献都包含了详细的元数据、原文摘要、中文翻译和AI的专业点评，敬请参考。

---

## 1. 设有与未设中级监护病房的医院ICU收治患者的结局、流程、利用率及成本测量：一项全国性住院患者数据库研究

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41217377](https://pubmed.ncbi.nlm.nih.gov/41217377)
**期刊：** Critical care medicine
**PMID：** 41217377
**DOI：** 10.1097/CCM.0000000000006962

### 第一部分 原文与翻译

**英文原标题：** Outcome, Process, Utilization, and Cost Measurements of Patients Admitted to the ICU in Hospitals With Vs. Without an Intermediate Care Unit: A Nationwide Inpatient Database Study.

**英文摘要原文：**
OBJECTIVE: To assess the impact of the presence of an intermediate care unit (IMCU) on ICU patient-level clinical outcomes as well as hospital-level utilization and cost measures by comparing those with vs without an IMCU, using Japan's nationwide inpatient database.

DESIGN: Nationwide retrospective cohort study.

SETTING: Acute-care hospitals in Japan participating in the Diagnosis Procedure Combination Study Group database and Hospital Bed Function Reports from 2016 to 2022.

PATIENTS: A total of 2,278,521 adult patients admitted to the ICU between April 2016 and March 2023.

INTERVENTIONS: ICU admission to hospitals with vs without an IMCU.

MEASUREMENTS AND MAIN RESULTS: Outcomes included patient-level (in-hospital and ICU mortality, ICU readmission, and length of ICU stay) and hospital-year level (resource utilization and hospitalization costs) measures. Among the 2,278,521 eligible ICU patients from 557 hospitals across 2,953 hospital-years, 1,771,000 (77.7%) patients were admitted to hospitals with both an ICU and IMCU. Overall, 14.3% of patients were transferred between the ICU and IMCU, with large variability between hospitals. When estimating participant-average treatment effect for patient-level outcomes, ICU patients in IMCU-equipped hospitals had lower in-hospital mortality (adjusted odds ratio [aOR] 0.94; 95% CI, 0.89-0.99), ICU mortality (aOR 0.87; 0.83-0.92), fewer ICU readmissions (aOR 0.92; 95% CI, 0.85-1.00), and shorter ICU stays (adjusted rate ratio 0.98; 95% CI, 0.98-0.99). When estimating cluster-average treatment effect for hospital-level outcomes, IMCU-equipped hospitals had higher ICU bed occupancy (mean difference: 5.5%, 95% CI, 3.3-7.7%), higher occupancy for life-sustaining therapies (8.6%, 95% CI, 7.7-9.5%), increased reimbursement rates (5.4%, 95% CI, 4.0-6.8%), and increased annual revenue per ICU bed (25 million JPY, 19-31 million JPY).

CONCLUSIONS: The presence of an IMCU in ICU-equipped hospitals was associated with improved patient outcomes and more efficient ICU utilization, with only modest increase in hospitalization costs. These findings support integration of the IMCU into critical care systems.

**中文摘要译文：**
目的： 本研究旨在利用日本的全国性住院患者数据库，通过比较设有与未设中级监护病房（IMCU）的医院，评估IMCU的存在对ICU患者层面的临床结局以及医院层面的资源利用率和成本指标的影响。

设计： 全国性回顾性队列研究。

地点： 2016年至2022年间，参与日本诊断程序组合研究组数据库和病床功能报告的急性期护理医院。

患者： 2016年4月至2023年3月期间，共计2,278,521名收治于ICU的成年患者。

干预措施： 患者被收治于设有IMCU的医院ICU与未设IMCU的医院ICU。

测量指标与主要结果： 结局指标包括患者层面（院内和ICU死亡率、ICU再入院率及ICU住院时长）和医院-年层面（资源利用率和住院成本）的测量。在来自557家医院、跨越2953个医院-年的2,278,521名符合条件的ICU患者中，1,771,000名（77.7%）患者被收治于同时设有ICU和IMCU的医院。总体而言，14.3%的患者在ICU和IMCU之间转科，且各医院之间存在较大差异。在评估患者层面结局的参与者平均治疗效应时，设有IMCU的医院其ICU患者的院内死亡率更低（调整后比值比[aOR] 0.94；95% CI, 0.89-0.99），ICU死亡率更低（aOR 0.87；0.83-0.92），ICU再入院率更少（aOR 0.92；95% CI, 0.85-1.00），ICU住院时长也更短（调整后率比 0.98；95% CI, 0.98-0.99）。在评估医院层面结局的集群平均治疗效应时，设有IMCU的医院其ICU床位占用率更高（平均差异：5.5%，95% CI, 3.3-7.7%），生命支持治疗的占用率更高（8.6%，95% CI, 7.7-9.5%），报销率更高（5.4%，95% CI, 4.0-6.8%），并且每张ICU床位的年收入也更高（2500万日元，1900万-3100万日元）。

结论： 在配有ICU的医院中，IMCU的存在与患者结局的改善和ICU利用效率的提升相关，而住院成本仅有适度增加。这些发现支持将IMCU整合到重症监护体系中。

### 第二部分 AI 大师评价

本研究基于日本全国性大型数据库，旨在探究中级监护病房（IMCU）对ICU患者临床结局及医院资源利用的实际影响。研究核心发现，配备IMCU的医院不仅显著改善了患者的关键指标，如降低死亡率和缩短ICU住院日，同时在医院层面也实现了更高的ICU床位利用率和经济效益。这项研究的价值在于，它为IMCU在现代重症监护体系中的整合提供了强有力的大数据证据，证实了其在提升患者护理质量与优化医疗资源配置方面的双重优势。

---

## 2. 达到目标体温的时间对心脏骤停幸存者是否重要？一项系统综述与荟萃分析

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41217361](https://pubmed.ncbi.nlm.nih.gov/41217361)
**期刊：** Critical care medicine
**PMID：** 41217361
**DOI：** 10.1097/CCM.0000000000006964

### 第一部分 原文与翻译

**英文原标题：** Does Time to Achieve a Targeted Body Temperature Matter for Survivors of Cardiac Arrest? A Systematic Review and Meta-Analysis.

**英文摘要原文：**
OBJECTIVES: To identify the impact of early hypothermic temperature control (HTC) initiation and achievement on neurologic outcomes after cardiac arrest. Secondary endpoints assessed: 1) overall survival, 2) body temperature at hospital admission, 3) time taken to reach targeted temperature, and 4) adverse events. Subgroup analyses assessed: 1) HTC induction method, 2) presenting rhythms (shockable vs. nonshockable), and 3) timing of HTC initiation (during cardiopulmonary resuscitation [CPR] vs. post-return of spontaneous circulation [ROSC]).

DATA SOURCES: PubMed, Cochrane Library, U.S. National Library of Medicine, MedRxiv, BioRxiv.

STUDY SELECTION: Prospective randomized controlled trials enrolling comatose adult cardiac arrest patients that assessed the efficacy of early cooling (defined by initiation of HTC within 30 min of ROSC) against late cooling.

DATA EXTRACTION: Two reviewers independently conducted study selection, data extraction, and assessment of evidence quality. Full texts were jointly reviewed, with discrepancies resolved by a third reviewer through discussion and consensus.

DATA SYNTHESIS: Of 7269 citations, 11 met the inclusion criteria. Early cooling did not improve neurologic outcomes (risk ratio [RR], 1.01; 95% CI, 0.94-1.14) nor survival (RR, 1.01; 95% CI, 0.92-1.11). Nasal evaporative cooling initiated during resuscitation may benefit patients with shockable rhythms (RR, 1.40; 95% CI, 1.00-1.96), while administering cold fluid during CPR was associated with a higher risk of rearrest. Cooling was initiated in the prehospital phase in ten studies, nine of which failed to achieve target temperature (32-34°C) by hospital admission. The median time to reach target temperature ranged from 38 to 360 minutes.

CONCLUSIONS: Early HTC showed no neurologic nor survival benefit in cardiac arrest survivors. Nasal evaporative cooling during CPR may benefit those with shockable rhythms. Delays in reaching the target temperature may underlie the failure of HTC. Future studies should evaluate whether achieving target temperature, for example, within 30 minutes, rapidly improves outcomes.

**中文摘要译文：**
目的：旨在明确早期启动并达成低温温度控制（HTC）对心脏骤停后神经系统结局的影响。次要终点包括：1) 总体生存率，2) 入院时体温，3) 达到目标温度所需时间，以及 4) 不良事件。亚组分析评估了：1) HTC诱导方法，2) 初始心律（可电击与不可电击心律），以及 3) HTC启动时机（心肺复苏[CPR]期间与恢复自主循环[ROSC]后）。

数据来源：PubMed、Cochrane图书馆、美国国家医学图书馆、MedRxiv、BioRxiv。

研究筛选：纳入评估早期降温（定义为ROSC后30分钟内启动HTC）相对于晚期降温疗效的前瞻性随机对照试验，研究对象为昏迷的成年心脏骤停患者。

数据提取：由两名评价员独立进行研究筛选、数据提取和证据质量评估。全文由两人共同审查，分歧通过第三名评价员的讨论和共识解决。

数据综合：在7269篇引文中，有11项研究符合纳入标准。早期降温未能改善神经系统结局（风险比[RR]为1.01；95% CI为0.94-1.14）或生存率（RR为1.01；95% CI为0.92-1.11）。在复苏期间启动的经鼻蒸发冷却可能对可电击心律患者有益（RR为1.40；95% CI为1.00-1.96），而在CPR期间输注冷液体则与再次心脏骤停风险增加相关。在十项研究中，降温措施在院前阶段启动，其中九项未能在入院时达到目标温度（32-34°C）。达到目标温度的中位时间范围为38至360分钟。

结论：早期HTC并未显示出对心脏骤停幸存者有神经系统或生存方面的益处。在CPR期间进行经鼻蒸发冷却可能对可电击心律患者有益。延迟达到目标温度可能是HTC失败的根本原因。未来的研究应评估快速达到目标温度（例如，在30分钟内）是否能改善结局。

### 第二部分 AI 大师评价

本研究通过系统综述与荟萃分析，旨在探究早期启动低温治疗对心脏骤停患者神经功能和生存率的影响。其核心发现是，仅仅“早开始”降温并不能带来显著获益，这挑战了传统观念。该研究的创新价值在于，它揭示了问题的关键可能不在于“启动”时机，而在于“达到”目标温度的速度，并指出现有院前降温措施的普遍延迟是疗法失败的潜在原因。此结论不仅对临床实践具有指导意义，也为未来研究指明了新方向，即优化降温技术以实现快速、高效的温度控制。

---

## 3. 人工智能、健康与医疗保健的今日与未来：《美国医学会杂志》人工智能峰会报告

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41082366](https://pubmed.ncbi.nlm.nih.gov/41082366)
**期刊：** JAMA
**PMID：** 41082366
**DOI：** 10.1001/jama.2025.18490

### 第一部分 原文与翻译

**英文原标题：** AI, Health, and Health Care Today and Tomorrow: The JAMA Summit Report on Artificial Intelligence.

**英文摘要原文：**
IMPORTANCE: Artificial intelligence (AI) is changing health and health care on an unprecedented scale. Though the potential benefits are massive, so are the risks. The JAMA Summit on AI discussed how health and health care AI should be developed, evaluated, regulated, disseminated, and monitored.

OBSERVATIONS: Health and health care AI is wide-ranging, including clinical tools (eg, sepsis alerts or diabetic retinopathy screening software), technologies used by individuals with health concerns (eg, mobile health apps), tools used by health care systems to improve business operations (eg, revenue cycle management or scheduling), and hybrid tools supporting both business operations (eg, documentation and billing) and clinical activities (eg, suggesting diagnoses or treatment plans). Many AI tools are already widely adopted, especially for medical imaging, mobile health, health care business operations, and hybrid functions like scribing outpatient visits. All these tools can have important health effects (good or bad), but these effects are often not quantified because evaluations are extremely challenging or not required, in part because many are outside the US Food and Drug Administration's regulatory oversight. A major challenge in evaluation is that a tool's effects are highly dependent on the human-computer interface, user training, and setting in which the tool is used. Numerous efforts lay out standards for the responsible use of AI, but most focus on monitoring for safety (eg, detection of model hallucinations) or institutional compliance with various process measures, and do not address effectiveness (ie, demonstration of improved outcomes). Ensuring AI is deployed equitably and in a manner that improves health outcomes or, if improving efficiency of health care delivery, does so safely, requires progress in 4 areas. First, multistakeholder engagement throughout the total product life cycle is needed. This effort would include greater partnership of end users with developers in initial tool creation and greater partnership of developers, regulators, and health care systems in the evaluation of tools as they are deployed. Second, measurement tools for evaluation and monitoring should be developed and disseminated. Beyond proposed monitoring and certification initiatives, this will require new methods and expertise to allow health care systems to conduct or participate in rapid, efficient, and robust evaluations of effectiveness. The third priority is creation of a nationally representative data infrastructure and learning environment to support the generation of generalizable knowledge about health effects of AI tools across different settings. Fourth, an incentive structure should be promoted, using market forces and policy levers, to drive these changes.

CONCLUSIONS AND RELEVANCE: AI will disrupt every part of health and health care delivery in the coming years. Given the many long-standing problems in health care, this disruption represents an incredible opportunity. However, the odds that this disruption will improve health for all will depend heavily on the creation of an ecosystem capable of rapid, efficient, robust, and generalizable knowledge about the consequences of these tools on health.

**中文摘要译文：**
重要性：人工智能（AI）正以前所未有的规模改变着健康和医疗保健。尽管其潜在益处巨大，但风险同样巨大。《美国医学会杂志》人工智能峰会探讨了应如何开发、评估、监管、传播和监测健康与医疗保健领域的人工智能。

观察：健康与医疗保健领域的人工智能应用范围广泛，包括临床工具（如脓毒症警报或糖尿病视网膜病变筛查软件）、有健康问题的个人使用的技术（如移动健康应用程序）、医疗系统用于改善业务运营的工具（如收入周期管理或排班），以及支持业务运营（如文档记录和计费）和临床活动（如建议诊断或治疗计划）的混合工具。许多人工智能工具已被广泛采用，尤其是在医学影像、移动健康、医疗保健业务运营以及门诊病历记录等混合功能方面。所有这些工具都可能产生重要的健康影响（无论好坏），但这些影响往往未被量化，因为评估工作极具挑战性或并非强制要求，部分原因在于许多工具不在美国食品药品监督管理局（FDA）的监管范围之内。评估中的一个主要挑战是，工具的效果高度依赖于人机交互界面、用户培训以及工具使用的具体环境。尽管已有众多努力为负责任地使用人工智能制定标准，但大多数标准侧重于安全性监测（如检测模型的幻觉）或机构对各种流程措施的合规性，而未涉及有效性（即证明能改善结局）。要确保人工智能的部署是公平的，并且能改善健康结局，或者在提高医疗服务效率的同时确保安全，需要在四个领域取得进展。首先，需要在产品的整个生命周期中让多方利益相关者参与进来。这项工作将包括在工具的初始创建阶段加强最终用户与开发者的合作，以及在工具部署后的评估阶段加强开发者、监管机构和医疗系统之间的合作。其次，应开发和推广用于评估与监测的测量工具。除了已提议的监测和认证举措外，这还需要新的方法和专业知识，以使医疗系统能够开展或参与快速、高效、稳健的有效性评估。第三个优先事项是创建一个具有全国代表性的数据基础设施和学习环境，以支持生成关于人工智能工具在不同环境下的健康影响的可推广知识。第四，应利用市场力量和政策杠杆，推行激励机制以驱动这些变革。

结论与相关性：在未来几年，人工智能将颠覆健康和医疗保健服务的每一个环节。鉴于医疗保健领域存在许多长期问题，这种颠覆代表了一个绝佳的机会。然而，这种颠覆能否改善所有人的健康，其可能性在很大程度上将取决于能否创建一个能够快速、高效、稳健地生成关于这些工具对健康之后果的可推广知识的生态系统。

### 第二部分 AI 大师评价

该JAMA峰会报告全面概述了人工智能在健康与医疗领域的现状、巨大潜力和并存风险。报告指出，当前AI工具在评估、监管和公平部署方面面临严峻挑战，尤其缺乏对临床有效性的量化证明。其核心价值在于前瞻性地提出了一个四维框架——涵盖多方合作、评估工具、数据基建和激励机制——为构建一个能稳健、高效评估AI健康影响的生态系统指明了方向。这为政策制定者、研究人员和临床医生提供了重要的战略指导，对推动AI技术负责任地变革医疗保健具有深远影响。

---

## 4. 关于实现机械通气患者个体化最佳氧疗的回复

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41066102](https://pubmed.ncbi.nlm.nih.gov/41066102)
**期刊：** JAMA
**PMID：** 41066102
**DOI：** 10.1001/jama.2025.14080

### 第一部分 原文与翻译

**英文原标题：** Reaching Individualized Optimal Oxygen Therapy in Mechanically Ventilated Patients-Reply.

**英文摘要原文：**
No abstract available.

**中文摘要译文：**
无可用摘要。

### 第二部分 AI 大师评价

该文献是一篇针对先前研究评论的“回复”，而非原创性研究论文。其核心在于回应关于机械通气患者个体化最佳氧疗策略的讨论，这在重症监护领域至关重要。由于没有摘要，该文可能旨在澄清其原始研究的方法、结果或结论，以回应同行的疑问。此类学术回应虽不提供新数据，但对于促进关键临床问题的深入探讨、完善科学共识具有重要价值。

---

## 5. 美国与吸入器相关的温室气体排放：一项系列横断面分析

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41051742](https://pubmed.ncbi.nlm.nih.gov/41051742)
**期刊：** JAMA
**PMID：** 41051742
**DOI：** 10.1001/jama.2025.16524

### 第一部分 原文与翻译

**英文原标题：** Inhaler-Related Greenhouse Gas Emissions in the US: A Serial Cross-Sectional Analysis.

**英文摘要原文：**
IMPORTANCE: Inhalers are the primary treatment modality for asthma and chronic obstructive pulmonary disease (COPD). Metered-dose inhalers contain hydrofluoroalkane propellants that contribute to substantial greenhouse gas emissions. The US federal government is facilitating a phasedown of hydrofluorocarbons over the next decade under international treaty obligations, yet current understanding of the scope and trajectory of inhaler-related emissions in the US remains incomplete.

OBJECTIVE: To quantify the magnitude, sources, and social costs of inhaler-related emissions in the US from 2014 to 2024.

DESIGN, SETTING, AND COHORT: This serial cross-sectional analysis estimated emissions from all inhalers approved for asthma or COPD using aggregated dispensing data across the US outpatient pharmaceutical market linked to estimated greenhouse gas emissions by inhaler.

EXPOSURES: All products were characterized based on their active pharmaceutical ingredients, device type, propellant type, therapeutic class, branded status, manufacturer, payer, and pharmacy benefit manager.

MAIN OUTCOMES AND MEASURES: Key end points included product utilization, greenhouse gas emissions (measured in carbon dioxide equivalents [CO2e] based on previously validated studies), and the social costs of emissions, which account for the net harms to society from greenhouse gases.

RESULTS: A total of 1.6 billion inhalers were dispensed in the US from 2014 to 2024, generating an estimated 24.9 million metric tons of CO2e (mtCO2e). Annual emissions increased by 24% from 1.9 million mtCO2e in 2014 to 2.3 million mtCO2e in 2024. Metered-dose inhalers were responsible for 98% of all emissions during the study period, and emissions were heavily concentrated among short-acting β-agonist, inhaled corticosteroid-long-acting β-agonist, and inhaled corticosteroid classes. Albuterol, budesonide-formoterol, and fluticasone propionate inhalers accounted for 87% of total emissions. The estimated social costs of emissions were $5.7 billion (lower bound, $3.5 billion; upper bound, $10.0 billion).

CONCLUSIONS AND RELEVANCE: Inhaler-related emissions in the US have increased over the past decade. Policymakers and regulators seeking to reduce emissions should identify targeted solutions aimed at shifting utilization to currently marketed dry powder and soft mist inhalers while facilitating the entry of newer, affordable metered-dose products containing propellants with low global warming potential.

**中文摘要译文：**
重要性：吸入器是治疗哮喘和慢性阻塞性肺疾病（COPD）的主要方式。定量吸入器含有氢氟烷烃抛射剂，会产生大量的温室气体排放。根据国际条约义务，美国联邦政府正在推动未来十年逐步减少氢氟碳化合物的使用，但目前对美国与吸入器相关的排放范围和趋势的理解仍不完整。

目的：量化2014年至2024年美国与吸入器相关的排放规模、来源及社会成本。

设计、地点和队列：本项系列横断面分析利用美国门诊医药市场的汇总配药数据，结合每种吸入器的估算温室气体排放量，对所有获批用于治疗哮喘或COPD的吸入器所产生的排放进行了估算。

暴露因素：所有产品均根据其活性药物成分、装置类型、抛射剂类型、治疗类别、品牌状态、制造商、支付方和药品福利管理者进行了表征。

主要结局和测量指标：关键终点包括产品使用情况、温室气体排放量（基于先前验证的研究，以二氧化碳当量[CO2e]衡量）以及排放的社会成本（该成本核算了温室气体对社会的净损害）。

结果：2014年至2024年，美国共配发了16亿支吸入器，估计产生了2490万公吨的二氧化碳当量（mtCO2e）。年排放量从2014年的190万公吨二氧化碳当量增加到2024年的230万公吨二氧化碳当量，增幅为24%。在研究期间，定量吸入器占所有排放量的98%，且排放主要集中在短效β-受体激动剂、吸入性皮质类固醇-长效β-受体激动剂以及吸入性皮质类固醇这几类药物中。沙丁胺醇、布地奈德-福莫特罗和丙酸氟替卡松吸入器占总排放量的87%。估算的排放社会成本为57亿美元（下限为35亿美元，上限为100亿美元）。

结论与相关性：在过去十年中，美国与吸入器相关的排放量有所增加。寻求减少排放的政策制定者和监管机构应确定有针对性的解决方案，旨在将使用转向目前市面上的干粉吸入器和软雾吸入器，同时促进含有低全球变暖潜能值抛射剂的、价格可负担的新型定量吸入器产品进入市场。

### 第二部分 AI 大师评价

该研究通过一项大规模的系列横断面分析，首次系统量化了2014至2024年间美国因哮喘和COPD治疗用吸入器产生的温室气体排放量、来源及社会成本。研究关键发现，十年间排放量呈上升趋势，其中含氢氟烷烃的定量吸入器是排放的绝对主要来源（占98%），造成了数十亿美元的社会环境成本。这项研究的创新性在于将临床药学数据与环境影响评估相结合，为公共卫生政策制定者提供了强有力的数据支持，凸显了推广干粉吸入器等环保替代疗法或开发低全球变暖潜能值抛射剂的紧迫性和重要价值。

---

速递结束，祝您工作愉快！